(secondQuint)A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT).

 This is an open-label (both physician and participant know the intervention), non-randomized (participants are not assigned by chance), multi-center study in untreated multiple myeloma participants who were not candidates for hematopoietic stem cell transplant.

 This study consists of two parts: Phase I and Phase II.

 In Phase I, a total of 18 participants will be enrolled ie, 6 patients per dose level (0.

7, 1.

0 and 1.

3 mg/m2) to determine the recommended dose of bortezomib.

 In Phase II, additional 83 participants will be enrolled.

 Safety evaluations will include assessment of adverse events, clinical laboratory test, specifically hematological toxicities.

.

 A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)@highlight

The purpose of the study in Phase I is to select the recommended dose of bortezomib in combination with melphalan and prednisolone in Japanese participants.

 In Phase II, to assess the effectiveness and safety of the recommended dose of bortezomib (selected in the phase I portion).

